Disparate Eosinophilic Phenotypes with Age: Impact on Eligibility for Anti-IL-5 Therapies in Severe Asthma

J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2697-2698. doi: 10.1016/j.jaip.2019.07.010.

Authors

Pieter-Paul Hekking¹, W Gerald Teague²

Affiliations

¹ Department of Pulmonology, Amsterdam University Medical Centre, Faculty of Medicine, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: p.w.hekking@amsterdamumc.nl.
² Division of Respiratory Medicine, Allergy, Immunology, and Sleep, Child Health Research Center, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Va.

PMID: 31706492
DOI: 10.1016/j.jaip.2019.07.010

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Asthma*
Humans
Phenotype

Substances

Antibodies, Monoclonal, Humanized
mepolizumab